JnJ Not Sweating Remicade Biosimilar Approval

Johnson & Johnson Inc. does not expect a biosimilar rival to its blockbuster tumor necrosis factor (TNF) inhibitor Remicade (infliximab) will launch in the US this year, despite the FDA approval of Celltrion Inc.'s Inflectra (infliximab-dyyb) April 5, and it remains comfortable with the growth outlook for pharmaceuticals.

"We don't expect biosimilar competition in 2016," Chief Financial Officer Dominic Caruso said during the company's first quarter sales and earnings call April 19